DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ultragenyx
Ultragenyx
PDF Version
NASDAQ Stock Market
ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant As Specified in Its Charter)
ULTRAGENYX PHARMACEUTICAL INC. (Exact Name of Registrant As Specified in Its Charter)
Year: 2017 Name: Amy Corneli Title: Associate Professor Address: 2200 West Main Street, Durham, NC 27705 Please Complete the Applicable Rows in the Following Table
2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
Active Labelers Run Date : Aug 28, 2018
Rebateable Manufacturers
Post-Event Summary
Representative Legal Matters Randall B
New Drug Approvals 201
Federated Kaufmann Large Cap Fund
Results Presentation Fiscal 2018 First Quarter
ULTRAGENYX PHARMACEUTICAL INC. (Name of Registrant As Specified in Its Charter)
Portola Pharmaceuticals Inc: Our Thoughts on Potential Competition
Arena Pharmaceuticals Appoints Three New Members to Board of Directors
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
MANUFACTURERS with CMS AGREEMENTS AS of 5-14-21 Labeler Code Labeler Name Program End Date 00002 ELI LILLY and COMPANY 00003 E.R
Top View
A Phase 3 Randomized Study Evaluating Sialic Acid Extended-Release for GNE Myopathy
The Evolving Role of Current and Novel Therapies in Improving Outcomes in Adults with PKU
Pdf Format Download
Development of Therapeutic Antibodies for the Treatment Of
Ultragenyx Appoints Dennis Huang As Chief Technical Operations Officer and Senior Vice President
Ultragenyx Appoints Sunil Agarwal, M.D. As Chief Medical Officer and Senior Vice President
ISPE SF 1-18-18 CEO Night Flyer
Orphans Should Live Alone
Companies in Attendance
Administrative Policy Statement WEST VIRGINIA MARKETPLACE PLAN Contents of Policy
PRELIMINARY PROGRAM Bay Area Discussion Group Co-Chairs: Min
For $320 Million to Royalty Pharma
Moderna 2021 Proxy Statement
Active Labelers Run Date : Aug 26, 2021
U.S. Pharmaceutical/Biotech Industry Update
Ventegra Overview
MCC Member Organizations
January 22, 2018
Inozyme Pharma Raises $49 Million in a Series a Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone
2604228.Pdf (1.914Mb)
RS PDF Biotech Data
The Bottom 99
List of Issuers with No Outstanding Past-Due Share of the Issuer Accounting Support Fee
Ultragenyx Pharmaceutical Inc. (Exact Name of Registrant As Specified in Its Charter)
Registered Drug Distribution Agents, Manufacturers Wholesalers As of 2/19/21
Rebateable Manufacturers
2021 Proxy Statement
FINAL PROGRAM CASSS Bay Area Discussion Group Co-Chairs: Min
Manufacturer's W/Start/End Dates and Sc Ind Appendix 1
Ultragenyx Appoints Camille L. Bedrosian, M.D. As Chief Medical Officer and Executive Vice President
Medical Affairs and Scientific Communications Forum
Biotechnology Fund
05/13/2021 Provider Subsystem Healthcare and Family Services Run Time: 20:39:26 Report Id 2794D052 Page: 01
Welcome to Analyst and Investor Day
Ultragenyx Pharmaceutical Inc